Aerie pharmaceuticals, inc. (AERI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities
Net loss

-199,581

-232,569

-145,105

-99,059

-74,363

-48,133

-31,148

-14,978

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation

5,100

2,400

1,400

970

252

73

64

138

Amortization and accretion

12,976

1,646

315

-

-

-

3,207

59

Amortization of debt issuance costs and fees

-

-

-

303

305

77

0

0

Amortization and accretion of premium or discount on investments, net

-

-

-

-525

-570

-416

0

0

Acquisition of assets expensed to research and development

10,171

0

24,802

0

0

-

-

-

Interest payablerelated parties

-

-

-

-

-

-

588

16

Loss (gain) on conversion of notes payable

-

-

-

-

-

-

-2,737

0

Stock-based compensation

45,093

38,728

26,078

16,794

12,945

9,178

2,858

430

Induced conversion of 2014 Convertible Notes

0

-24,059

0

0

-

-

-

-

Other non-cash

271

270

-601

-

-

-

-

-

Unrealized foreign exchange (gain) loss

-

-

-

0

0

-

-

-

Change in fair value measurements

-

-

-

-

-

-

-3,717

-630

Changes in operating assets and liabilities
Accounts receivable, net

35,639

2,715

0

0

-

-

-

-

Inventory

10,257

9,689

0

0

-

-

-

-

Prepaid, current and other assets

2,144

791

2,239

1,852

840

717

516

-9

Accounts payable, accrued expenses and other current liabilities

28,766

26,583

925

2,479

5,385

4,829

2,045

-1,272

Increase (Decrease) In Operating Lease, Liability

4,700

-

-

-

-

-

-

-

Interest payable

-

-

-

-

-

551

0

0

Net cash used in operating activities

-150,430

-152,576

-93,213

-79,840

-55,746

-33,726

-16,448

-14,968

Cash flows from investing activities
Acquisition of assets

7,835

0

10,500

0

0

-

-

-

Purchase of available-for-sale investments

165,454

56,195

104,490

35,169

46,872

95,376

0

0

Proceeds from sales and maturities of investments

0

108,297

88,153

58,346

59,534

-

-

-

Maturity of available-for-sale investments

-

-

-

-

-

20,739

0

0

Sale of available-for-sale investments

-

-

-

-

-

1,500

0

0

Purchase of property, plant and equipment

9,958

31,313

15,970

5,077

3,280

181

63

51

Net cash provided by (used in) investing activities

-183,247

20,789

-42,807

18,100

9,382

-73,318

-63

-51

Cash flows from financing activities
Proceeds from Issuance of Common Stock

0

135,972

134,215

167,383

50,451

0

0

-

Payments related to issuance of stock for stock-based compensation arrangements, net

684

3,630

1,429

1,242

-

-

-

-

Payments of stock issuance costs and expenses

-

-

-

-

-

0

-

-

Dividends paid

-

-

-

-

-

-

-

130

Proceeds from exercise of stock options

-

-

-

-

-

9

1

6

Proceeds from exercise of stock purchase rights

-

-

-

-

-

119

0

0

Tax withholdings related to restricted stock awards

-

-

-

-

-

0

-

-

Proceeds from exercise of warrants

761

0

0

-

-

0

8

0

Proceeds from convertible notes, net of issuance costs

308,349

0

0

-

-

-

-

-

Payments of initial public offering costs

-

-

-

-

-

-

71,870

0

Proceeds from notes payable to related parties

-

-

-

-

-

-

3,644

0

Proceeds from notes payable to related parties

-

-

-

-

-

-

15,000

3,000

Payments of issuance costs

1,769

1,883

0

0

-

-

-

0

Payment for capped call options

32,890

0

0

-

-

-

-

-

Proceeds related to issuance of stock for stock-based compensation arrangements, net

684

3,630

1,429

1,242

1,387

-

-

-

Other financing

-336

-683

0

0

-

-

-

-

Payments of debt issuance costs

-

-

-

-

-

122,853

0

0

Net cash used in financing activities

274,799

137,036

135,644

168,625

51,838

122,981

83,235

2,876

Net change in cash and cash equivalents

-58,878

5,249

-376

106,885

5,474

15,937

66,724

-12,143

Supplemental disclosures
Cash paid for interest

6,496

1,774

2,188

2,192

2,186

0

0

0

Cash paid for income taxes

-

-

-

1,790

600

0

0

-

Conversion of convertible notes to common stock (Note 10)

0

148,078

0

0

-

-

-

-

Equity issued for Envisia Asset Acquisition

0

0

14,302

0

-

-

-

-

Liabilities incurred from Avizorex Asset Acquisition

1,186

0

0

-

-

-

-

-

Purchase of property, plant and equipment

771

3,526

4,176

482

-

-

-

-

Acquisition of capital lease obligation

0

0

689

0

0

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

61,348

0

Conversion of convertible notes payable and accrued interest to common stock

-

-

-

-

-

-

18,604

0

Issuance of common stock upon net exercise of warrants

-

-

-

-

-

-

4,888

0

Reclassification of warrants from liabilities to equity

-

-

-

-

-

-

6,560

0

Debt discount attributable to warrants

-

-

-

-

-

-

-

728

Accretion from conversion of note payable to related parties

-

-

-

-

-

-

240

292

Accretion of stock issuance costs

-

-

-

-

-

-

210

258

Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction

0

0

403

70

0

25

0

0

Build-to-suit lease transaction (Note 7)

-

-

-

-

0

-

-

-